MAT
58
2
HOG
44
2
PNW
64
-2
XYL
30
-2
VTR
46
-4
TRIP
66
6
MDLZ
57
-6
HPE
59
13
HIG
63
4
AEP
56
-2
MPC
59
7
DO
48
4
XRX
48
7
WFC
41
-9
DIS
49
-3
ED
50
-2
PVH
57
10
MOS
45
3
V
60
2
PNR
59
2
MAT
58
2
HOG
44
2
PNW
64
-2
XYL
30
-2
VTR
46
-4
TRIP
66
6
MDLZ
57
-6
HPE
59
13
HIG
63
4
AEP
56
-2
MPC
59
7
DO
48
4
XRX
48
7
WFC
41
-9
DIS
49
-3
ED
50
-2
PVH
57
10
MOS
45
3
V
60
2
PNR
59
2
Financhill
Back

Kiniksa Pharmaceuticals Quote, Financials, Valuation and Earnings

Prepare now for a ChatGPT IPO announcement

Click here to see more
Buy
69

KNSA
Kiniksa Pharmaceuticals

Last Price:
17.77
Seasonality Move:
11.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Is Elon Musk right about AI?

Learn all about it here.

Kiniksa Pharmaceuticals Price Quote

$17.77
+0.01 (+3.07%)
(Updated: September 2, 2023 at 6:15 AM ET)

Kiniksa Pharmaceuticals Key Stats

Buy
69
Kiniksa Pharmaceuticals (KNSA) is a Buy
Day range:
$17.26 - $17.89
52-week range:
$10.14 - $20.65
Dividend yield:
0%
P/E ratio:
6.83
P/S ratio:
4.47
P/B ratio:
3.03%
Volume:
251.3K
Avg. volume:
630.5K
1-year change:
48.37%
Market cap:
$1.2B
Revenue:
$220.2M
EPS:
$3.27

How Much Does Kiniksa Pharmaceuticals Make?

Is Kiniksa Pharmaceuticals Growing As A Company?

Kiniksa Pharmaceuticals Stock Price Performance

What Is Kiniksa Pharmaceuticals 52-Week High & Low?

Kiniksa Pharmaceuticals Price To Free Cash Flow

Is It Risky To Buy Kiniksa Pharmaceuticals?

Is Kiniksa Pharmaceuticals Cash Flow Positive?

  • What Is KNSA Cash Flow From Operations?
    Cash flow from operations (TTM) is $42.5M
  • What Is Kiniksa Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $1.8M
  • What Is Kiniksa Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$26M

Kiniksa Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    KNSA return on invested capital is 66.63%
  • What Is Kiniksa Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is 56.2%
  • What Is KNSA Return On Equity?
    ROE is a measure of profitability and is 66.63%

Kiniksa Pharmaceuticals Earnings Date & Stock Price

Kiniksa Pharmaceuticals Competitors

Kiniksa Pharmaceuticals Dividend Yield

Data Unavailable

Kiniksa Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 261.54%
Revenue: 164.99% 36.93%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 25.40
Upside from Last Price: 43.02%

Major Shareholders

  • How many KNSA shares are owned by institutional investors?
    48.7M KNSA shares are owned by institutional investors
  • How many KNSA shares are owned by insiders?
    778.2K KNSA shares are owned by insiders